1379P Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort ADaniel V.T. Catenacci, Y-K. Kang, D-Y. Oh et al.|Annals of Oncology|2021Cited by 14
516MO Phase I/II study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignanciesH. Park, Ecaterina E. Dumbrava, Geoffrey I. Shapiro et al.|Annals of Oncology|2021Cited by 1